
|Articles|October 1, 2002
Commitment to R&D strengthens Allergan product pipeline
Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: A new biomechanical paradigm for presbyopia
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
4
Managing Unique Dry Eye Disease Subtypes in Patients
5

















































.png)


